RFM
IONS icon

Royal Fund Management’s Ionis Pharmaceuticals IONS Stock Holding History

Royal Fund Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10
Closed – – 340
2020
Q1 		$0 Hold
10
– – ﹤0.01% 654
2019
Q4 		$0 Hold
10
– – ﹤0.01% 665
2019
Q3 		$0 Buy
+10
New +$652 ﹤0.01% 624

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Royal Fund Management's IONS Position: Q2 2020 in Review

Royal Fund Management sold out of Ionis Pharmaceuticals (IONS) in Q2 2020, closing a stake of 10 shares.

Royal Fund Management first reported a position in IONS in Q3 2019 and held it in 3 quarters. The position peaked at $0 in Q1 2020. 375 funds tracked by Wall St. Rank hold IONS as of Q2 2020.

  • Royal Fund Management reported no remaining Ionis Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Royal Fund Management sold 10 Ionis Pharmaceuticals shares in Q2 2020.
  • Royal Fund Management first reported a position in Ionis Pharmaceuticals in Q3 2019 and held it in 3 quarters.
  • Royal Fund Management's Ionis Pharmaceuticals position peaked at $0 in Q1 2020.
  • 375 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2020.

Based on Royal Fund Management's 13F filing for Q2 2020, filed 6 Aug 2020.